Brian McMillan is current Founder, CEO and President of Bravado Pharmaceuticals in Lutz Florida. McMillan is a Pharmaceutical Development scientist with over 30 years of Analytical and Formulation Development Experience at nationally acclaimed laboratories such as Roxane Laboratories, Bausch and Lomb Pharmaceuticals, and MDS Pharma Services as well as co-founder and CTO of CoreRx Inc. located in Clearwater Florida. McMillan specializes in developing multi-layer tablet dosage forms, combination products, and bio-availability enhancement utilizing complexation and solid-state dispersion among other techniques. Brian has also developed ophthalmic, solid oral, liquid oral, semi-solid, parenteral, and topical dosage forms over the course of his career which includes development or part of over approximate 200 products.
During his time at Bausch and Lomb Pharmaceuticals, McMillan was the lead formulator and process development scientist for RetisertTM, a sterile implant designed to release fluocinolone acetonide locally to the posterior segment of the eye. RetisertTM is the world’s first intravitreal drug implant for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. After joining CoreRx he developed “Peramivir” (trade name Rapivab) in solution, suspension, and lyophilized form. “Rapivab” is an anti-viral for the treatment of pandemic H1N1. The US government stockpiled the lyophilized form for H1N1. At Core he also developed over a dozen analgesic oral solution products, and various formulations for both IR and MR mono and multi-layer tablet systems. McMillan was the lead scientist for the FDAs first approved drug for weight loss ContraveTM in monolayer, bi-layer and tri-layer format. McMillan was also lead scientist on TesoRx oral Testosterone “TSX-049”. TSX-049 is a novel, oral formulation of Testosterone (T) containing Testosterone Undecanoate (TU) that is designed to help restore normal Testosterone levels in males with hypogonadism. Also, at CoreRx he was initial formulator of “PALFORZIA” a treatment for people who are allergic to peanuts. PALFORZIA can help reduce the severity of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut. During his career McMillan has worked on or developed over 200 dosage forms. Most recently at Bravado McMillan has been the lead formulator for CoVer Nasal Antibody Drops. The product was developed as a collaboration in the battle against Covid-19 with Stanford University and SPARK GLOBAL. The formulation forms an antibody blockade preventing CV19 from entering through the nasal cavity where it binds to the ACE receptor.
In addition to his other duties, he has been an assistant professor of pharmacy at the University of South Florida’s College of Pharmacy teaching pre-formulation and formulation development of various dosage forms. In his Medicinal Chemistry program at the University of Florida, McMillan harvested, synthesized, and elucidated natural product molecules in collaboration with Smithsonian Marine Institute, Fort Pierce, Florida. These molecules were high in antioxidant properties, which could have efficacy as anti-cancer products and age longevity. He has also been a keynote speaker on JRS PHARMA’s (the world leader in tablet excipient technology) annual advisory board and has worked with JRS on tablet excipient technology development.
The University of Florida, Gainesville, Florida, Ph.D. Graduate Student Medicinal Chemistry, Fall 2013 to Fall 2015
The University of Florida, Gainesville, Florida, M.S. in Pharmacy with concentration in Pharmaceutical Chemistry, May 2013
The Ohio State University, Columbus, Ohio, B.A. Biochemistry, June 1989, Major area of studies in The College of Pharmacy